Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of roxadustat versus epoetin alfa for anemia in dialysis patients with chronic kidney disease
2014-000780-40Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of roxadustat in anaemia and chronic kidney disease (CKD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Major adverse cardiovascular events (MACE). Started Oct 2014; status: completed.
02
Drugs
roxadustat
03
Conditions
anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2014-000780-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000780-40.